YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24,…
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at 16.00 pm in Orexo's f…
OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioids If approved, the US launch is expected to be initiated in H1 2024…
UPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5), EBITDA excluding legal costs and costs for non-…
Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability Orexo has initiated two exploratory feasibility studies applying amorphOX® to a protein based…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
Virtual Investor Conferences Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com MORRISTOWN, N.J., Dec. 14, 2022 (GLOBE…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
UPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal costs and costs for non-repe…
Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) The study enrolled 437 participants at 35 sites across th…
Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) The study enrolled 437 participants at 35 sites across th…
UPPSALA, Sweden, Oct. 26, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new Chief Medical Officer (CMO). Ed Kim will succeed Michael Sumner, M.D., who has held this role since 2013…
UPPSALA, Sweden, Oct. 17, 2022 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) that will take place on April 18, 2023, a Nomination Committee has been appointed comprising the same members as ahead of the AGM hosted earlier this…
All four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine Data available today indicates significantly improved stability compared to current standard of…
UPPSALA, Sweden, Sept. 7, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital…
UPPSALA, Sweden, Sept. 1, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline…
STOCKHOLM, Aug. 31, 2022 /PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and evidence-based digital therapeutics primarily targeting the US market where its commercial organization is loca…
UPPSALA, Sweden, July 14, 2022 /PRNewswire/ -- Good tailwind in the financial development Q2 2022 highlights Total net revenues of SEK 147.8 m (142.8) EBITDA of SEK -32.5 m (-41.1) Net earnings of SEK -35.8 m (-73.7) US Pharma segment (ZUB…
Orexo is granted a Veterans Affairs Federal Supply Schedule contract for deprexis® in the US and will be reimbursed and made available by the federal government for use within the Veterans Affairs Health System, Indian Health Service and D…
OX640 has the potential to provide important benefits to patients and healthcare systems ensuring the correct adrenaline dose is both reliably and conveniently available - for the emergency treatment of allergic reactions If approved, the…
Virtual Investor Conferences NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor For…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
UPPSALA, Sweden, April 28, 2022 /PRNewswire/ -- Promising start to 2022 Q1 2022 highlights Total net revenues of SEK 159.4 m (132.3) EBITDA of SEK 2.8 m (-23.9) Net earnings of SEK -23.6 m (-31.5) US Pharma segment (ZUBSOLV® US) net revenu…
UPPSALA, Sweden, April 27, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of syst…
UPPSALA, Sweden, April 21, 2022 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 21 April 2022 resolved, in accordance with the nomination committee's proposal, that the number…
UPPSALA, Sweden, March 11, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new Chief Financial Officer (CFO) and a member of the management team, starting a…
- ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 - ZUBSOLV® market access improves in the public segment to 48 percent unrestricted access from 42 percent currently - ZUBSOLV® mainta…
The development pipeline is broadening with a nasal adrenaline medication, targeting a global and growing unmet medical need If approved, the medication would provide important benefits to patients and health care systems ensuring the corr…
- amorphOXTM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products with various active ingredients and administration routes - The amorphOXTM platform provides for excellent chemical and…
- The pivotal trial OX124-002 meets the primary endpoints in the4-period crossover, comparative bioavailability study in healthy volunteers - OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular d…
- Steady progression on our journey to build a broader and stronger Orexo UPPSALA, Sweden, Nov. 3, 2021 /PRNewswire/ -- Q3 2021 highlights Total net revenues of SEK 145.9 m (150.3) Net earnings of -52.0 SEK m (-84.9) EBITDA of SEK -47.4 m…
UPPSALA, Sweden, Nov. 1, 2021 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percent of the number of votes in the company as of September 30,…
Commentary published in the Journal of Medical Internet Research (JMIR) Mental Health MORRISTOWN, N.J., Oct. 18, 2021 /PRNewswire/ -- Today Orexo announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral…
UPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for A…
The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the second half of 2022. OX124 is designed to reverse the effect of overdoses caused by the most powerful synthetic opioids that today are…